Amyl Therapeutics
Amyl Therapeutics is a preclinical-stage biotechnology company developing Pan-Amyloid Immunotherapy, a universal approach to treating amyloid-mediated neurodegenerative diseases. Their mission is to develop a treatment that targets all toxic amyloid species across neurodegenerative and systemic amyloid-mediated diseases, with the potential to be both preventative and curative. The company is supported by an experienced team and strategic collaborations, aiming to transform the standard of care for amyloid-related diseases.
Industries
Nr. of Employees
small (1-50)
Products
Pan-amyloid immunotherapy candidates (preclinical)
Preclinical therapeutic candidates designed to selectively bind the structural signature common to amyloid fibrils (cross-β sheet), intended to neutralize multiple toxic aggregates and clear mature fibrils while minimizing inflammatory risk and improving CNS exposure.
Pan-amyloid immunotherapy candidates (preclinical)
Preclinical therapeutic candidates designed to selectively bind the structural signature common to amyloid fibrils (cross-β sheet), intended to neutralize multiple toxic aggregates and clear mature fibrils while minimizing inflammatory risk and improving CNS exposure.
Services
Preclinical candidate discovery and development (internal)
End-to-end preclinical R&D activities to discover, optimize and characterize immunotherapeutic candidates targeting amyloid aggregates.
Preclinical candidate discovery and development (internal)
End-to-end preclinical R&D activities to discover, optimize and characterize immunotherapeutic candidates targeting amyloid aggregates.
Expertise Areas
- Preclinical immunotherapy development
- Neurodegenerative disease therapeutics (amyloid-mediated)
- Cross-amyloid targeting strategies
- Antibody and biologic engineering for CNS delivery
Key Technologies
- Antibody-based immunotherapy
- Targeting cross-β sheet amyloid conformation
- AI-driven molecule optimization
- Bioassay development and analytics